John Provenza, MD
Gastroenterology · Shreveport, LANPI 1225028434
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 533 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,499 and has fallen 54.6% since, to $680 in 2025.
Across 533 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Pfizer$1K
- Johnson & Johnson$971
- Takeda Pharmaceuticals U.S.A., Inc.$751
- Sanofi$394
- plus $2K from 24 others
Across 22 payments — averaging $2998.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$37K
- Adare Pharmaceuticals, Inc.$14K
- Shire North American Group Inc$9K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
What the payments were for
- Food & beverage$8,40397%
- Education$2763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $1,830 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 121 | $1,650 |
| Pfizer | 74 | $1,123 |
| Johnson & Johnson(2 entities) | 44 | $971 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $751 |
| Sanofi | 16 | $394 |
| Daiichi Sankyo Inc. | 18 | $353 |
| Bristol Myers Squibb | 35 | $332 |
| Merck | 20 | $317 |
| Ironwood Pharmaceuticals, Inc | 5 | $83 |
| Phathom Pharmaceuticals, Inc. | 5 | $83 |
| E.r. Squibb & Sons, L.L.C. | 1 | $81 |
| Redhill Biopharma Inc. | 4 | $71 |
| UCB, Inc. | 4 | $70 |
| Gilead | 3 | $62 |
| Nestle Healthcare Nutrition Inc. | 3 | $57 |
| Intercept Pharmaceuticals, Inc. | 3 | $56 |
| Cumberland Pharmaceuticals, Inc. | 3 | $47 |
| Amgen | 2 | $43 |
| QOL Medical, LLC | 2 | $40 |
| Evoke Pharma, Inc. | 2 | $35 |
| Novo Nordisk | 2 | $34 |
| AstraZeneca | 1 | $33 |
| Braintree Laboratories, Inc. | 2 | $30 |
| Lilly USA, LLC | 2 | $29 |
| Medtronic | 1 | $27 |
| Sandoz | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Celltrion USA Inc. | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$124
How this compares
$8,678 in reported general payments places this provider in the 75th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 16 | $442,919 |
| OcalivaObeticholic Acid | 17 | $157,504 |
| RemicadeInfliximab | 13 | $97,179 |
| ZenpepLipase/Protease/Amylase | 14 | $56,173 |
| LinzessLinaclotide | 35 | $31,548 |
| TrulancePlecanatide | 18 | $11,929 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 248 | $5,567 |
| Budesonide DrBudesonide | 41 | $4,952 |
| Colestipol Hcl | 40 | $4,396 |
| Esomeprazole Magnesium | 164 | $3,887 |
| Budesonide EcBudesonide | 17 | $3,311 |
| Ursodiol | 13 | $2,587 |
| Colesevelam Hcl | 11 | $2,047 |
| Azathioprine | 18 | $1,500 |
| Sucralfate | 14 | $1,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Remicade | $971 | $540,09829 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $56 | $157,50417 claims |
| AbbVieLinzess | $1,830 | $31,54835 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $1,650 | $11,92918 claims |
| SandozLansoprazole | $20 | $23415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Shreveport
- Humberto AguilarShreveport$313K
- Hrishikesh SamantShreveport$81K
- Sathya JaganmohanShreveport$25K
- Qiang CaiShreveport$14K
- Elvin HardyShreveport$13K
- James MorrisShreveport$11K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Charles MonierThibodaux$448K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.